08:00 |
 |
EPAG Workshop – Registration and Refreshments |
|
09:00 - 12:00 |
 |
EPAG Workshop Perspectives on recent changes in regulatory, academia & science that impact OINDP products The European Pharmaceutical Aerosol Group (EPAG), would like to share and discuss recent changes in regulatory, academia & science that impact OINDP products. This workshop is free to attend but you must register to attend by following the link below: |
|
11:00 |
|
DDL2025 Registration Exhibition Hall and Poster Hall Open Level -2 Refreshments served in both halls |
|
12:00 - 13:15 |
 |
Networking Lunch in the Exhibition Hall and Poster Hall Network with delegates and view the industry exhibition and poster exhibition. Lunch is served in the exhibition hall and the poster hall. |
|
12:00 - 13:00 |
 |
The DDL New Researcher Networking Lunch Paired Networking Session – for new and early career scientists and PhD students only. Lowther Meeting Room, Level -1 |
|
13:15 |
 |
Conference Opens Welcome by |
|
13:35 |
 |
From Inhaled Drugs to Exhaled Viruses: A Journey of my 45 years in Aerosol Medicine. The DDL Lecture is a prestigious accolade bestowed on individuals who have contributed much to the field of respiratory science. |
|
14:05 - 14:50 |
SESSION 1 -ADVANCES IN PRECLINICAL DRUG DEVELOPMENT |
||
14:10 |
 |
Integrating innovative AI and Human-Relevant Models: Transforming and Accelerating Respiratory Drug Development |
|
14:35 |
 |
Inter-individual variability in human primary nasal cells to evaluate new nasally inhaled treatments. |
|
14:50 - 16:10 |
 |
Refreshment Break Explore the exhibition stands and network with delegates Manned Poster Session – JUDGING The poster exhibition is on Level -2. Poster presenters will be interviewed by the DDL Judges to be considered for the Best Academic and Best Industry Poster at DDL2025. Please allow judges to take priority in talking to the authors during this session. Another manned poster session is scheduled during the Thursday morning refreshment break |
|
16:10 - 17:30 |
SESSION 1 CONTINUED -ADVANCES IN PRECLINICAL DRUG DEVELOPMENT |
||
16:15 |
 |
Advances in in vitro endpoints for inhaled drug delivery safety assessment |
|
16:30 |
 |
Precision-cut lung slices as a platform to investigate cytotoxicity and efficacy of novel therapeutics |
|
16:45 |
 |
Effect on lung permeation of various formulation efforts invested in the inhaled antibiotic apramycin as measured in the ex vivo isolated, perfused, and ventilated rat lung |
|
17:00 |
 |
A multi-tiered approach to inhalation risk assessment – Development of advanced in vitro models for pre-clinical safety |
|
17:30 - 20:00 |
 |
Welcome Drinks Reception Networking across the conference centre, with drinks and canapes in the exhibition hall and the poster hall. |
|
17:30 - 18:30 |
|
The New Researcher Network – ‘Career Cocktail’ Evening For new and early career researchers and PhD Students only. Lowther Meeting Room, Level -1 With invited guests. |
08:00 |
|
Registration and Refreshments |
|
09:00 - 10:40 |
SESSION 2: MAKING INNOVATION HAPPEN This interactive session explores the many faces of entrepreneurial success through two real-world case studies—one highlighting a university spin-out acquisition, the other a startup that concluded with valuable lessons and growth. |
||
09:00 - 09:30 |
 |
From Ideas to Products in Aerosol Drug Delivery (ADD): Barriers to Innovation PLENARY |
|
09:35 - 10:40 |
Case study discussion Topics that will be addressed: Invited speakers:
|
||
10-40 - 11:45 |
|
Refreshment Break Explore the exhibition stands and network with delegates Manned Poster Session The poster exhibition is on Level -2. Authors will be at their posters to discuss them with the attendees. |
|
11:45 |
Winner of The DDL2025 Emerging Scientist Award Announced The winner of this award will be announced live on stage and will present their research. This award recognises significant scientific accomplishment or innovation during the early stages of an individual’s career in inhalation science. |
||
11:50 |
 |
The DDL2025 Emerging Scientist Winner’s Presentation |
|
12:30 |
 |
Switches Between pMDI and DPI Asthma Preventers in England: Discontinuation, Persistence and Switch-back Plenary |
|
12:55 - 14:20 |
|
Networking Lunch in the Exhibition Hall and Poster Hall Network with delegates, visit the exhibition stands and view the conference posters. Lunch is served in the exhibition hall and poster hall. |
|
14:20 - 15:40 |
SESSION 3: THE PAT BURNELL YOUNG INVESTIGATOR AWARD Finalists present their work and are judged by the DDL Organising Committee The winner of the competition will be announced following the day’s lectures in the Pentland Auditorium. This award recognises the vision of Pat Burnell and has been designed to encourage junior researchers from either academia or industry to present their work at the DDL Conference. |
||
14:25 |
 |
3D Airway Models for In Vitro Studies and Drug Delivery |
|
14:40 |
 |
Development of Inhalable Phage-Encapsulated Liposomes for improved delivery against Pseudomonas aeruginosa Lung Infections |
|
14:55 |
 |
Locust Bean Gum Microcarriers for Lung Immunomodulation: In Vivo Efficacy Assessment |
|
15:10 |
 |
Inhaled Plasminogen for ARDS: from feasibility to in vivo efficacy and stabilize under simulate oxygen therapy administration |
|
15:25 |
 |
The Development of an Inhalable Platelet-Based Therapy for Lung Injury |
|
15:40 - 16:45 |
|
Refreshment Break Explore the exhibition stands and the poster exhibition and network with delegates |
|
16:45 - 17:45 |
SESSION 4: TO THE AIRWAYS AND BEYOND |
||
16:50 |
 |
Challenges associated with solid state biologic aerosols |
|
17:15 |
 |
Powder Deagglomeration in a Chaotic Flow: An Introduction to the O1 High Payload DPI Device |
|
17:30 |
 |
Turning Down the Heat – Nano Spray Drying of RNA Encapsulating LNPs at Room Temperature |
|
17:45 |
|
Awards Ceremony Join us in the Pentland Auditorium as we announce the winners of:
|
|
18:00 - 20:00 |
|
Networking Drinks Reception Networking across the conference centre, with drinks and canapes in the exhibition hall and the poster hall. |
Dr Jag Shur,
Charlotta Gummeson
Panel discussion – all speakers
08:00 |
|
Morning Refreshments Explore the exhibition stands and the poster exhibition and network with delegates before the lecture programme begins for the final day |
|
09:00 - 09:45 |
SESSION 4 CONTINUED: TO THE AIRWAYS AND BEYOND |
||
09:05 |
 |
Inhaled Oxytocin (IHO): Adventures in Pharmacokinetics and Bioanalysis to Save Mothers’ Lives Associate Professor (Practice) Pete Lambert, Monash University |
|
09:30 |
 |
From Prediction to Performance: ML-Guided Co-Amorphous Rifampicin Formulations for Inhalation Therapy in Tuberculosis Dr Sarah Zellnitz-Neugebauer, Research Center Pharmaceutical Engineering GmbH |
|
09:45- 11:15 |
|
Refreshment Break Explore the exhibition stands, view the conference posters and network with delegates |
|
11:15 - 12:30 |
SESSION 4 CONTINUED: TO THE AIRWAYS AND BEYOND |
||
11:20 |
 |
Nose-to-Brain Delivery – A narrow shortcut towards the CNS |
|
11:45 |
 |
Evaluating the transport and intracellular uptake of drugs across nasal epithelial cells and neuroblastoma cells |
|
12:00 |
 |
Development and characterization of in situ hydrogels for nasal delivery of antibiotics using the Alberta Idealized Nasal Inlet (AINI) |
|
12:15 |
 |
Inhalable Nanoagglomerate Powder of Cholecalciferol for Nose-to-Brain Delivery: A Promising First-Aid Therapy for Ischemic Stroke |
|
12:30 |
|
Closing remarks |
01 |
 |
A Framework for Combining the Principles of QbD and Quality Risk Management for Metered Dose Inhaler Components |
|
02 |
 |
Improving the performance of low-GWP pMDIs via exit cone angle adjustment |
|
03 |
 |
Suspension assessment of Salmeterol Xinafoate, Formoterol Fumarate Dihydrate and Glycopyrronium Bromide in HFA-152a and HFA-134a |
|
04 |
 |
Velocity Profiles of Current and Low GWP Propellant pMDI Spray Plumes |
|
05 |
 |
Formulating HFO-1234ze(E) pMDIs with Ethanol: Flammability Considerations |
|
06 |
 |
Comparison of the Aerodynamic Performance of Pressurized Metered Dose Inhalers Manufactured by Respitab™ and Drum Dose Dry Filling
Chen Zheng , Cardiff Scintigraphics Ltd/i2c pharmaceutical services |
|
07 |
 |
Delivered Dose Method Development for an Ethanol Free, Dual API Suspension Formulated in HFA152a |
|
08 |
 |
Investigating the Impact of Probe Positioning on pMDI Plume Temperature |
|
09 |
 |
Achieving Consistent MDI Drug Delivery Data: The Role of the Rockstar Automation Platform in Through-Can-Use-Life Characterization |
|
10 |
 |
A Case Study Using Spray Pattern Analysis to Evaluate Actuators from a pMDI Suspension Product |
|
11 |
 |
Impact of Inhalation Excipients on a Distal Lung Epithelium In Vitro Model |
|
12 |
|
The Impact of Permeation Enhancers on Improving the Permeability of Spray-Dried Leuprolide Formulations Using RPMI-2650 Cells |
|
13 |
 |
Simvastatin and rapamycin reduces IL 8 release in BEAS 2B cells- implication for inhalational therapy of neutrophillic asthma |
|
14 |
 |
A Dry Powder Aerosolization Device for In vitro Applications Coming to Life: Optimization and Validation |
|
15 |
 |
Development of an in vivo assay for aggregation and macrophage uptake of inhaled biologics |
|
16 |
 |
Efficacy of an inhalable paclitaxel nanoagglomerate dry powder formulation in in vitro air-liquid interface-cultured lung cancer organoid and in vivo orthotopic lung cancer mouse models |
|
17 |
 |
Inhalable Vardenafil Dry Powder Formulation with Improved Bioavailability |
|
18 |
 |
Intracellular pharmacokinetic/pharmacodynamic modelling of PEG12-KL4/siRNA nanocomplex for developing pulmonary delivery |
|
19 |
|
3D Airway Models for In Vitro Studies and Drug Delivery
Aurélie Marches , Malmö University |
|
20 |
 |
Garcinoic acid: from Garcinia kola seeds extraction to an innovative delivery system for nose-to-brain delivery |
|
21 |
 |
A strategy for the formulation screening of spray-dried polymeric lipid hybrid nano-in-microparticles (PLNiM) for nasal delivery |
|
22 |
 |
Inhalable PLGA Microparticles: A Targeted Approach to Tuberculosis Treatment |
|
23 |
 |
pH-responsive polymersomes for eradication of Pseudomonas aeruginosa biofilm in chronic rhinosinusitis
Amalie Kjær Andresen , Technical University of Denmark (DTU) |
|
24 |
 |
Investigation of In-vitro Aerosolisation Performance for Alginate-based Bioaerogel Microparticles |
|
25 |
 |
β-lactoglobulin (Dispersome®) as a Novel Pharmaceutical Excipient for Enhancing the Aerosolization Efficiency of Dry Powder Inhalation Formulations |
|
26 |
 |
Porous particles as dual micro-nano carriers for dry powder inhalation of small drugs and proteins |
|
27 |
 |
Development and Evaluation of Paeoniflorin-loaded Silk Fibroin Microspheres for Potential Pulmonary Drug Delivery: From In Vitro to In Vivo Studies |
|
28 |
 |
Softpellets – a new production equipment |
|
29 |
 |
Optimisation of excipient selection for production of stable inhalable dry powders of a monoclonal antibody using spray drying |
|
30 |
|
Development of Inhalable Phage-Encapsulated Liposomes for improved delivery against Pseudomonas aeruginosa Lung Infections
Shruti Sawant , Purdue University |
|
31 |
 |
Assessing the Performance of a New Apparatus for Orally Inhaled Product Dissolution Testing in the Differentiation of Alternative Commercial Products for the Delivery of Fluticasone Propionate |
|
32 |
 |
Efficacy evaluation of controlled-release budesonide dry powder for inhalation for moderate-to-severe asthma in guinea pigs |
|
33 |
 |
Dissolution Behavior of Inhalable Dry Powder Formulations: Unravelling the Influence of Solubility Across iBCS Classes |
|
34 |
 |
Intranasal brain targeting of poorly soluble and permeable drugs by designing an easily scalable self-emulsifying sprayable nasal delivery platform |
|
35 |
 |
Pulmonary and Systemic Exposure to Zanamivir in Healthy and ALI Rats |
|
36 |
 |
The combination of PEG12KL4 peptide and lipid nanoparticles (LNPs) for pulmonary mRNA delivery via nebulisation |
|
37 |
 |
Potential of the in vitro dissolution method DissolvIt® to predict pharmacokinetic outcomes |
|
38 |
|
Inhaled Plasminogen for ARDS: from feasibility to in vivo efficacy and stabilize under simulate oxygen therapy administration
Lucia Vizzoni , University of Siena |
|
39 |
|
CFD Modelling of Suspension Mixing Process for pMDIs: Lab-Scale Manufacturing Process Insights and Scale-Up Potential |
|
40 |
 |
Development of Inhaler Add-Ons for the Enhancement of Aerosol Drug Deposition in the Lungs |
|
41 |
 |
From Impinging Jets to Single Jet Impaction: A Preliminary Study on an Alternative Nozzle Concept for the Respimat® Soft Mist Inhaler
Moritz Fleischhauer , Boehringer Ingelheim/ Johannes Gutenberg University Mainz |
|
42 |
 |
Investigation of Dry Powder Inhaler (DPI) Dose Aerosolization and Transport During Transient Airflows from Stationary to Target Flow Rate |
|
43 |
 |
Utilizing Molecular Dynamics Simulations for Understanding RNA-Lipid Nanoparticle Lactose Interactions |
|
44 |
 |
From Prototype to Platform: Portable Injection-Moulded PBM-Hale™ Enables Non-Invasive, Low-Leachables, Saliva-Free Exhaled Breath Condensate Sampling for Drug and Biomarker Analysis |
|
45 |
 |
Evaluation of the Effect of Fines in Powder Blends in Combination with a Novel Capsule-based Dry Powder Inhaler Device |
|
46 |
 |
Precision Inhalation Therapy: From Guided Patient Inhalation to Real-Time Patient-Specific Pulmonary Drug Deposition
Marion Blayac , Institute of Lung Health and Immunity (LHI), Helmholtz Center Munich |
|
47 |
 |
Bridging Engineering and End-users: The Importance of Usability in Device Innovation |
|
48 |
 |
Target-Oriented Aerosol Design: Predicting Particle Characteristics to Achieve Desired Lung Deposition |
|
49 |
 |
Analysis of mRNA Delivery Performance via Vibrating Mesh Nebulization |
|
50 |
 |
Transfection efficiency of mRNA-LNPs after aerosolization with Rayleigh breakup based SMIs |
|
51 |
 |
Generation of DNase-Enzymosomes: Towards the Production of Inhalable Dry Powder Formulations |
|
52 |
 |
Development of cationic and ionizable LNPs for intranasal delivery: The influence of PEGylation on formulation characteristics |
|
53 |
 |
Development of mRNA lipid nanoparticles for the delivery of gene editing tools to the lungs
Sjoerd Hak , Department of Biotechnology and Nanomedicine, SINTEF |
|
54 |
 |
A novel, innovative Approach targeting Inflammatory Lung Diseases – Regulatory T-cell Delivery to the Lungs |
|
55 |
 |
Stabilising Nebulised mRNA-Lipid Nanoparticles Using PEG-Lipid Alternatives |
|
56 |
 |
Efficient Pulmonary Delivery of Nucleic Acid-Loaded Lipid Nanoparticles (LNPs) Using the MRX004 Soft-Mist Inhaler |
|
57 |
 |
Calixaren as novel gene vector formulated within spray-dried inhalable powders |
|
58 |
 |
KIT2014, a Dual Inhaled PDE3/4 Inhibitor Enhancing Epithelial Function in the Airways |
|
59 |
 |
Innovative nebulisation delivery of GalNAc conjugated siRNA – a potential route for systemic drug delivery through the lungs |
|
60 |
 |
Optimisation of the Nebu~Flow Nebuliser to Enable Shear-Free Aerosolisation of Fragile Large Molecules |
|
61 |
 |
Nebulisation of Antisense Oligonucleotide (ASO) Danvatirsen |
|
62 |
 |
A Systematic Approach to Evaluate the Robustness of NGI Methods for the Determination of Aerodynamic Particle Size Distribution (APSD) in Dry Powder Inhalers |
|
63 |
 |
Cold-Stage MDRS Investigation of Beclomethasone Dipropionate: In Situ Monitoring Morphological and Chemical Stability of Nasal Spray API Across Different Temperatures |
|
64 |
 |
Worldwide Development and Commercialization of a Drug Product: harmonization of FDA and EMA analytical requirements |
|
65 |
 |
Early Comparison of Spray-Drying and Ball Milling for Amorphous Tiotropium Bromide Preparation: Insights from DVS and Complementary Techniques |
|
66 |
 |
Analytical Considerations for Nitrosamine Formation when Formulating pMDI’s with Next-Generation Low GWP Propellant Systems |
|
67 |
 |
In Vitro Scoping Study of a Dry Powder Inhaler Using Clinically Possible Abnormal Inhalation Profiles for Emitted Aerosol Aerodynamic Particle Size Distribution at Low Peak Inspiratory Flow Rates |
|
68 |
 |
The Challenges of Developing a Purity Method for the Analysis of a Single Dose DPI Inhaler |
|
69 |
 |
Laser Doppler Vibrometry as a Process Analytical Tool for Spray Drying Manufacturing |
|
70 |
 |
Investigation of the Solid-State Properties of a Neurosteroid Intended for Respiratory Delivery |
|
71 |
 |
Effect of counselling on inhalation technique from metered-dose inhaler alone and with AeroChamber2go and MDI PLUS spacers |
|
72 |
|
Pressurized metered dose inhalers alone and connected to aerochamber2go and MDI PLUS spacers: In-vitro and in-vivo study |
|
73 |
 |
Pharmaceuticals in The Environment: Recent Progresses for An Effective and Responsible Environmental Risk Management |
|
74 |
 |
Impact of the Aptar Digital Health respiratory disease management platform on adult asthma |
|
75 |
 |
Life Cycle Assessment of the Environmental Impact of Respiratory Drug Products: From API to Device |
|
76 |
 |
Implications for Patient Experience: Comparison of Plume Characteristics from Pressurized Metered Dose Inhalers (pMDIs) Formulated with Hydrofluoroalkane (HFA) and Near-Zero Global Warming Potential Hydrofluoroolefin (HFO-1234ze |
|
77 |
 |
Product vs Human Factors – Assessment of Automated and Manual Shaking Parameters on Through Life Dose Performance of Symbicort pMDI |
|
78 |
 |
“after 40 years of using an inhaler, I’ve not a single clue of how I’m supposed to use it”: A call to action… |
|
79 |
 |
Assessment of real-world patient inhalation techniques with a Metered Dose Inhaler and Smart Spacer: Which errors are observed and can these be addressed through tailored education? |
|
80 |
 |
Development of inhaled high-dose antibiotics formulations for acute lower respiratory tract infections |
|
81 |
 |
Seeing the Unseen: Analysis of a Novel Dry Water Formulation for Nasal Inhalation |
|
82 |
 |
Scalable Atomisation for Spray Dried Powders for Nasal Delivery |
|
83 |
 |
Engineering a Medical Device for Intranasal Immunization: Ensuring Targeted Delivery and Formulation Stability |
|
84 |
 |
The Effect of Coating Nasal Casts with Mucus Simulants on the Regional Deposition of Sumatriptan
Lucy Goodacre , King’s College London and Nanopharm Ltd, an Aptar Pharma Company |
|
85 |
|
Aerosolisation and Nasal Deposition of siRNA Lipid Nanoparticle Using a Targeted Nasal Spray Device |
|
86 |
 |
Retaining the Dose: How Cast Material and Particle Properties Affect Nasal Powder Rebound |
|
87 |
 |
Nasal Levodopa: An On-Demand Delivery System for the Management of Parkinson’s Disease |
|
88 |
 |
Nose-to-Brain Delivery of Urtica dioica Phytosterols for Cholesterol Modulation in Neurodegeneration |
|
89 |
 |
Assessing the impact of different flow rates on drug delivery from a novel nasal DPI |
|
90 |
 |
From pills to sprays: rethinking antiemetics in pregnancy |
|
91 |
 |
Geometric morphometrics approach for predicting olfactory region accessibility
Priya Vishnumurthy , Aix-Marseille University (UMR7343 CNRS AMU) / Nemera |
|
92 |
 |
A Modified KinetiSol Process to Produce Dry Powder Blends for Pulmonary Delivery |
|
93 |
 |
Semaglutide powder for inhalation manufactured through a novel process and its aerodynamic and in vitro performance |
|
94 |
 |
Navigating the Spray Drying Process: Impact of Bulking Excipients on Nasal Powder Manufacture and Process Scalability |
|
95 |
 |
The role of leucine in stabilizing inhalable dry powder formulations |
|
96 |
 |
Electrostatic Charging of Spray Dried Salbutamol Sulfate Aerosols: Effect of excipient L-leucine |
|
97 |
 |
Spray dried Co-crystals of Itraconazole and Succinic acid for Inhalation Therapy |
|
98 |
 |
Lipid and amino acid shell formers as aerosolization- and stability-enhancers in spray-dried high-dose amorphous drug product |
|
99 |
 |
Mitigating colloidal instability in inhaled spray dried lipid nanoparticles using an amorphous shell former |
|
100 |
 |
Evaluating the In Vitro Regional Deposition Characteristics and Stability of a Spray Dried Tuberculosis Vaccine Candidate |
|
101 |
 |
Comparative In-Silico Evaluation of 4′-Fluorouridine and Favipiravir Pulmonary Delivery via PEGylated Graphene Oxide Nanocarriers
Oluwasegun Chijioke Adekoya , Tshwane University of Technology (TUT) |
|
102 |
 |
Computational Modelling of Metering Chamber Refill in Pressurised Metered Dose Inhalers with Current and Next Generation Propellants |
|
103 |
 |
The viscous limit for Soft Mist Inhalers; an in-silico study |
|
104 |
 |
Application of AI Techniques for Misuse Detection Using a Digital Motion Monitoring Module for Dry Powder Inhalers |
|
105 |
 |
An Enhanced Approach to Predicting Site Specific Inhaled Drug Deposition in Humans via In-Vitro and In-Silico Data Fusion |
|
106 |
 |
Fibrous particles as a drug form for inhalation therapy: in vitro and in silico study
Jana Kánská , Faculty of Mechanical Engineering, Brno University of Technology |
|
107 |
 |
Bridging In Vitro and Anatomy-Informed Predictive Modeling to Optimize Pediatric Intranasal and Pulmonary Drug Delivery |
|
108 |
 |
Sensitivity analysis of Guided Stream Technology for targeting the olfactory area using an anatomically relevant nasal cast |
|
109 |
 |
NAVETTA in Action: In Vitro Simulation of Budesonide DPI Delivery and Efficacy
Sandra Verstraelen , Flemish Institute for Technological Research (VITO) |
|
110 |
 |
Mechanism Underlying the Influence of liquid formulation physical properties on Aerosol Particle Size Distribution in Mesh Membrane Nebulization |
|
111 |
 |
Machine Learning-Driven Investigation of a Microfluidic Manufacturing Process of Nanoparticles for Intranasal Delivery |
|
112 |
 |
A statistical approach for carrier particle optimisation – Design of Experiments & Bayesian Optimisation |
|
113 |
 |
Process Understanding and Control: Scale-Up of Low Shear Blending for DPI Formulations |
|
114 |
 |
Integrating Device Engineering and User-Centred Design for High-Performance Dry Powder Inhalers Using a Particle-Engineered Formulation |
|
115 |
 |
From Concept to Final Formulation: A Structured Development of Lipid-Based Nanoemulsions for Dry Powder Inhalation |
|
116 |
 |
Investigation of high pulmonary drug loading to the lung using a novel lactose grade with iDPC blending technology |
|
117 |
 |
Pharmacokinetic Profile Investigation of Pulmonary Semaglutide Engineered Powder |
|
118 |
 |
Physical Stability of Dry Powder Formulations Studied One Particle at a Time |
|
119 |
 |
Impact of nitrocellulose-free foil on dry powder inhaler product performance and stability |
|
120 |
 |
Non-destructive microstructural characterisation of inhalation blends in-situ within capsules |
|
121 |
 |
Impact of Blistering Process on the Aerodynamic Performance of Capsules Filled with a Lipid-based Dry Powder for Inhalation |
|
122 |
 |
Magnesium stearate as a force control agent in dry powder inhalation – revisiting the mechanism of action |
|
123 |
 |
Assessment of the Effect of Fluticasone Furoate Morphology on the In Vitro Performance of a Dual Blister Dry Powder Inhaler |
|
124 |
 |
Investigation of the scalability of DPI blends produced by resonant acoustic mixing and the comparability with blends produced using high shear mixing |
|
125 |
 |
Simvastatin Dry Powder for Treatment of Non-Small Cell Lung Cancer and In Vitro Characterisation |
|
126 |
 |
Validation of In-Silico Lung Deposition Predictions for Inhaled Liposomal Amikacin Against Scintigraphy Data |
|
127 |
 |
Addressing the need for high-throughput testing of breath-actuated nebulizers |
|
128 |
 |
Enhancing Delivery Performance of Viscous Solutions with a Customisable Breath-actuated Mesh Nebuliser Platform |
|
129 |
 |
Integration of a Novel Electronic Facemask with Airflow Sensing and Nebulizer Aerosol Delivery |
|
130 |
 |
Getting an inhaled antibiotic innovation, Colistin Cyclops®, to CF patients in the CFTR modulator era |
|
131 |
 |
Effect of Nebulizer Breath-Guiding on Breathing Patterns |
|
132 |
 |
Performance of the Aerogen A-VMN vibrating mesh in combination with budesonide |
|
133 |
 |
Development and Characterisation of a Semaglutide Nasal Drug Product |
|
134 |
 |
Improvement of the drug delivery in vibrating mesh inhalers using piezoelectric micro pumps |
|
135 |
 |
The Effect of Using Face Masks on the Delivered Dose of Nebulised Salbutamol |